Masashi Takano

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 19:1259-64. 2008
  2. pmc Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
    M Takano
    Department of Obstetrics and Gynaecology, National Defence Medical College, Tokorozawa, Saitama 359 8513, Japan
    Br J Cancer 94:1369-74. 2006
  3. ncbi request reprint Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 16:1301-6. 2006
  4. ncbi request reprint Preoperative needle biopsy and immunohistochemical analysis for gastrointestinal stromal tumor of the rectum mimicking vaginal leiomyoma
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 16:927-30. 2006
  5. ncbi request reprint Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3 2, Tokorozawa, Saitama, 359 8513, Japan
    Int J Clin Oncol 12:256-60. 2007
  6. doi request reprint ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Saitama, Japan
    Histopathology 60:1073-83. 2012
  7. doi request reprint Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:122-30. 2012
  8. doi request reprint Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 20:1506-10. 2010
  9. doi request reprint The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 19:1353-7. 2009
  10. doi request reprint Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:615-24. 2012

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 19:1259-64. 2008
    ..03) and that the chemotherapeutic regimen was not a prognostic factor (p=0.43). The present study indicates that we should accomplish complete surgical staging procedures for CCC confined to the ovary...
  2. pmc Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
    M Takano
    Department of Obstetrics and Gynaecology, National Defence Medical College, Tokorozawa, Saitama 359 8513, Japan
    Br J Cancer 94:1369-74. 2006
    ..02). Our results suggest that cytoreductive surgery resulting in no residual tumour only could improve the prognosis of advanced CCC patients...
  3. ncbi request reprint Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 16:1301-6. 2006
    ..However, this is a limited retrospective study, therefore we recommend that the CPT-P regimen be evaluated in a larger prospective study...
  4. ncbi request reprint Preoperative needle biopsy and immunohistochemical analysis for gastrointestinal stromal tumor of the rectum mimicking vaginal leiomyoma
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 16:927-30. 2006
    ..Preoperative biopsy with vaginal approach might be helpful to make a diagnosis for pelvic tumor of unknown origin and unknown malignant potential...
  5. ncbi request reprint Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3 2, Tokorozawa, Saitama, 359 8513, Japan
    Int J Clin Oncol 12:256-60. 2007
    ..Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC)...
  6. doi request reprint ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Saitama, Japan
    Histopathology 60:1073-83. 2012
    ..2, enhances cell motility by bundling the actin cytoskeleton. We assessed how ACTN4/actinin-4 alterations contribute to the tumorigenesis of ovarian clear-cell adenocarcinomas (CCAs)...
  7. doi request reprint Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:122-30. 2012
    ....
  8. doi request reprint Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 20:1506-10. 2010
    ..However, CCC often showed chemo-resistant phenotype, and the effect of adjuvant chemotherapy still remained uncertain...
  9. doi request reprint The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 19:1353-7. 2009
    ..More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology...
  10. doi request reprint Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:615-24. 2012
    ....
  11. doi request reprint Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 22:499-507. 2009
    ..The actinin-4 gene may be a target of the 19q amplicon, acting as a candidate oncogene, and serve as a predictor of poor outcome and tumor chemoresistance in patients with advanced-stage ovarian cancers...
  12. doi request reprint Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Onkologie 32:595-7. 2009
    ..Palliative therapy is usually employed for the treatment of metastatic or relapsed cervical cancer. Many agents including cisplatin have been used for fighting the tumor; however, the gold standard therapy has not yet been confirmed...
  13. doi request reprint Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer
    Ei ichiro Tominaga
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku ku, Tokyo, Japan
    Gynecol Oncol 118:160-6. 2010
    ..The purpose of this study was to identify genes that predict progression-free survival (PFS) in advanced epithelial ovarian cancer (aEOC) receiving standard therapy...
  14. doi request reprint Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases
    Yuji Ikeda
    Department of Obstetrics and Gynecology, Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 23:355-60. 2013
    ..Here, we evaluated the effect of weekly low-dose administration of GEMOX in combination with bevacizumab (B-GEMOX) for patients with recurrent and refractory ovarian cancers (ROCs)...
  15. doi request reprint Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Int J Clin Oncol 16:605-9. 2011
    ..In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial...
  16. doi request reprint Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 30:431-41. 2011
    ..On the basis of the prognostic impact and interobserver reproducibility, the present binary classification system for CCAs was deemed to be highly superior to the compared conventional histologic grading system...
  17. ncbi request reprint The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
    Tsunekazu Kita
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Gynecol Oncol 92:813-8. 2004
    ..The purpose of this study was to reconfirm the effect of weekly paclitaxel in more number of cases...
  18. doi request reprint Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 30:129-38. 2011
    ..These results suggest that the 2 tested grading systems have limited value for the prognostication of patients with clear cell adenocarcinoma, and that a more effective grading system for this tumor may be required...
  19. doi request reprint Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Japan
    Int J Gynecol Pathol 31:116-24. 2012
    ..The proposed grouping system could divide patients with CCA into 3 subgroups with distinct prognostic indications, providing a 3-tier histological grading system for ovarian CCA...
  20. doi request reprint Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary
    Kosuke Miyai
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 29:321-7. 2010
    ..These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity...
  21. doi request reprint Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defence Medical College, Tokorozawa, Saitama, Japan
    Histopathology 56:740-9. 2010
    ..To identify the key cell-cycle dysregulations in the development of endometriosis-associated ovarian clear cell adenocarcinoma (CCA)...
  22. doi request reprint Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Virchows Arch 455:413-22. 2009
    ....
  23. doi request reprint Identification of potential serum markers for endometrial cancer using protein expression profiling
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    J Cancer Res Clin Oncol 136:475-81. 2010
    ..Screening method of endometrial cancer (EC) has not been established yet. Our study was to explore serum biomarkers of EC patients using surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS)...
  24. doi request reprint Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    Kazuya Kudoh
    Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japan
    Gynecol Oncol 122:233-7. 2011
    ..We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC...
  25. doi request reprint Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Saitama, Japan
    Mod Pathol 24:1146-55. 2011
    ..MET could serve as a biomarker for the prognostication of patients with clear-cell adenocarcinoma and tumor progression, and has potential as a novel therapeutic target for this carcinoma...
  26. ncbi request reprint Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Mod Pathol 21:115-24. 2008
    ....
  27. doi request reprint Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers
    Tomoko Goto
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 21:263-8. 2011
    ..The purpose of this study was to explore the potential survival benefit of SCS in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers...
  28. doi request reprint Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
    Tatsuyuki Chiyoda
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
    Genes Chromosomes Cancer 51:229-39. 2012
    ..TGF-beta signaling is activated in CS and chromosomal gains at 19q13, which includes the TGFB1 locus, suggest that this may contribute to high expression of TGF-beta and thereby EMT phenotype of CS...
  29. doi request reprint PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defence Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    J Pathol 225:189-94. 2011
    ..A specific kinase inhibitor to mutated PIK3CA may potentially be an effective therapeutic reagent against these carcinomas...
  30. ncbi request reprint Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers
    Tomoko Goto
    Department of Obstetrics and Gynecology, Saitama Medical College, Iruma gun, Saitama 350 0495, Japan
    Oncol Rep 15:1265-71. 2006
    ..004). RhoGDI expression proved to be a predictive marker of paclitaxel resistance not only in paclitaxel-resistant cell lines, but also in clinical samples...
  31. ncbi request reprint Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study
    Satoshi Takakura
    Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
    Int J Gynecol Cancer 20:240-7. 2010
    ..Combination chemotherapy with irinotecan hydrochloride plus cisplatin has been reported to be effective for primary and recurrent or resistant CCC. We compared these 2 combinations in patients with CCC...
  32. doi request reprint Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas
    Sadako Nishimura
    Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka, Japan
    Int J Gynecol Cancer 20:220-6. 2010
    ..In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs...
  33. doi request reprint PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Virchows Arch 460:77-87. 2012
    ..013). PIK3CA gene mutations and ARID1A immunohistochemistry lacked prognostic significance. These data further support the idea that these molecular alterations occur as very early events during tumor development of ovarian CCA...
  34. ncbi request reprint Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer
    Shizuo Machida
    Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan
    Oncology 65:102-7. 2003
    ..We performed a phase I clinical study to evaluate combination chemotherapy with irinotecan hydrochloride (CPT-11) and nedaplatin (CPT-11/nedaplatin) for cervical cancer...
  35. doi request reprint An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Virchows Arch 455:261-70. 2009
    ..These data further support the presence of two distinct carcinogenic pathways to ovarian clear-cell adenocarcinoma; the allelic status of the 3p, 5q, and 11q loci may provide a means to identify the precursor lesions of these carcinomas...
  36. doi request reprint Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma
    Masafumi Kato
    Departments of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 31:254-63. 2012
    ..Expressions of p-mTOR, HIF-1α, and Glut1 have already been evident in the putative precursor lesions of CCA, and these alterations cumulatively occur in the development of ovarian CCA...
  37. pmc Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review
    Morikazu Miyamoto
    Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan
    J Gynecol Oncol 24:37-43. 2013
    ..In the present study, multivariate analysis to compare prognosis of CCC patients with that of SAC was aimed for the patients selected from central pathologic review...
  38. ncbi request reprint [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement]
    Masashi Takano
    Dept of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Gan To Kagaku Ryoho 35:1981-4. 2008
    ..Therefore, we do recommend that special cautions are required for the bevacizumab- based chemotherapy, especially severely pretreated ovarian cancer patients...
  39. ncbi request reprint Treatment options in the management of ovarian cancer
    Yoshihiro Kikuchi
    Department of Obstetrics and Gynecology, National Defence Medical College, Tokorozawa, Saitama 359 8513, Japan
    Expert Opin Pharmacother 6:743-54. 2005
    ..Cautious optimism should prevail for all investigators involved in translating these exciting new biological findings into new pharmacological agents for treatment of cancer...
  40. doi request reprint Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women
    J Obstet Gynaecol Res 39:872-5. 2013
    ..The progression-free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2...
  41. pmc Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    J Exp Clin Cancer Res 31:53. 2012
    ..In this review article, we discuss the surgical issues for early-staged and advanced CCC including possibility of fertility-sparing surgery, and the chemotherapy for CCC disease...
  42. doi request reprint High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway
    Kosuke Yoshihara
    Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Clin Cancer Res 18:1374-85. 2012
    ..Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients...
  43. doi request reprint p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer
    Tomoko Goto
    Department of Gynaecologic Oncology, Saitama Medical University International Medical Centre Comprehensive Cancer Centre, 1397 1 Yamane, Hidaka, Saitama, Japan
    Int J Cancer 125:339-44. 2009
    ..Our data suggest that p16INK4a expression in cytology of ascites is a candidate marker in prediction of the primary response to chemotherapy and prognosis...
  44. ncbi request reprint Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Mod Pathol 20:1278-85. 2007
    ..Accumulation of actinin-4 in the cytoplasm may be related to a higher propensity for tumor invasiveness and metastasis, probably by enhancing cell motility, and could be a novel prognostic indicator for patients with ovarian carcinomas...
  45. ncbi request reprint Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    Oncol Rep 12:1177-82. 2004
    ..01). We concluded that the cytoplasmic overexpression of MUC1 might be an indicator of resistance to platinum-based chemotherapy and a prognostic marker in ovarian cancer...
  46. doi request reprint Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection
    Toyomi Satoh
    Department of Obstetrics and Gynecology, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba, Ibaraki 305 8575, Japan
    J Clin Oncol 28:1727-32. 2010
    ..The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC)...
  47. ncbi request reprint Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan
    Anticancer Res 22:1833-8. 2002
    ..In this phase I trial, 80 mg/m2/week of paclitaxel was recommended as the phase II dose for outpatients...
  48. ncbi request reprint Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    Gynecol Oncol 91:444-8. 2003
    ..A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature...
  49. ncbi request reprint Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia
    Tomoko Goto
    Department of Obstetrics and Gynecology, Saitama Medical College, 38 Morohongo, Iruma gun, Saitama 350 0495, Japan
    Oncol Rep 15:387-91. 2006
    ..Thus, expression of PIK3CA was observed in liquid-based cytology in CIN lesions, which suggested its diagnostic significance in addition to the use of routine cervical cancer smear and the HPV screening program...
  50. ncbi request reprint Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems
    Tomoko Goto
    Department of Obstetrics and Gynecology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama 359 8513, Japan
    Adv Exp Med Biol 665:171-9. 2009
    ....
  51. ncbi request reprint Successful management of cervical pregnancy by selective uterine artery embolization: a case report
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    J Reprod Med 49:986-8. 2004
    ..Cervical pregnancy is potentially associated with life-threatening hemorrhage and often requires hysterectomy to stop the bleeding. Conservative management is becoming more common as treatment of cervical pregnancy...
  52. ncbi request reprint [The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma]
    Kazuyuki Fujii
    Dept of Obstetrics and Gynecology, National Defense Medical College
    Gan To Kagaku Ryoho 31:1537-40. 2004
    ..We suggested that Paclitaxel combination chemotherapy with Shakuyaku-Kanzo-to taken orally is a more safe and tolerable way to reduce pain in epithelial ovarian carcinoma...
  53. ncbi request reprint [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer]
    Naoki Sasaki
    Department of Gynecology and Obstetrics, National Defense Medical College
    Nihon Rinsho 62:582-6. 2004
  54. ncbi request reprint [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma]
    Kazuyuki Fujii
    Dept of Obstetrics and Gynecology, National Defense Medical College
    Gan To Kagaku Ryoho 31:2141-4. 2004
    ..But we have many chemoresistant cases, and we examined the efficacy of weekly, single-agent, paclitaxel administration...